Therefore, therapies targeting HDAC6 may restore balanced mitochondrial activity, mediate potential repair of peripheral neuropathy, and alleviate neuropathic pain (Adalbert et al., 2020). This evidence concerns the gene HDAC6 and peripheral neuropathy.